Philip Morris International (NYSE: PM) has entered a contract manufacturing arrangement with Altria (NYSE: MO) for combustible cigarettes. The deal leverages shared capabilities while PMI maintains its focus on smoke-free products.

First shipments under the agreement are expected to begin early in 2027, subject to operational readiness and regulatory requirements. PMI stated it does not expect a material impact on its 2026 financials from this arrangement.

Strategic Context

PMI has not commercialized combustible cigarettes in the United States and has no plans to do so. The arrangement will not change that stance. Both companies will continue to operate independently, maintaining responsibility for their own commercialization, distribution, and regulatory activities.

The collaboration aims to leverage the respective combustible cigarette manufacturing capabilities and expertise of both organizations. This aligns with PMI’s broader strategy of delivering a smoke-free future while optimizing existing infrastructure.

Smoke-Free Business Metrics

As of December 31, 2025, PMI estimates its smoke-free products were used by over 43 million legal-age consumers globally. The smoke-free business accounted for approximately 42% of PMI’s second-quarter 2026 total net revenues. Products are available in over 105 markets.

Since 2008, PMI has invested over $16 billion to develop and commercialize innovative smoke-free products. This includes heat-not-burn, nicotine pouch, and e-vapor products. The U.S. Food and Drug Administration has authorized marketing for versions of PMI’s IQOS devices and consumables, as well as Swedish Match’s General snus and ZYN nicotine pouches.

What the Numbers Show

The data reveals a significant divergence between PMI’s capital allocation and its legacy business footprint in the U.S. market. While the company invests heavily in smoke-free alternatives—evidenced by the $16 billion cumulative spend and 42% revenue contribution in Q2FY26—it is simultaneously entering a manufacturing partnership for combustible cigarettes with Altria. This suggests a strategic decoupling of production efficiency from product portfolio direction, allowing PMI to maintain operational synergies without altering its long-term exit strategy from U.S. combustible sales.

The US Food and Drug Administration (FDA) has authorized the marketing of 11 ZYN ULTRA moist oral nicotine pouch products for Philip Morris International Inc. (NYSE: PM). The approval covers all nine 9mg variants and one 11mg variant of the tobacco-free product line.

This regulatory action strengthens Philip Morris International’s position in the US smoke-free category. The FDA issued Marketing Granted Orders to PMI’s US affiliate, Swedish Match USA Inc., following a scientific review. Additional 11mg variants remain under review.

Product Portfolio Expansion

The authorized products feature higher moisture content compared to standard pouches. They are free of tobacco leaf. The approvals build on earlier FDA authorizations for ZYN in multiple flavors and lower nicotine strengths (3mg and 6mg).

Authorized Variants

Stacey Kennedy, CEO of PMI US, stated the decision builds on ZYN’s position as America’s leading smoke-free product brand. The company aims to expand choices for the 45 million Americans who consume nicotine products.

Regulatory Context

The FDA determined that permitting the marketing of these new tobacco products is appropriate for the protection of public health. This follows recent modified risk tobacco product orders for certain previously authorized ZYN nicotine pouches.

Philip Morris International began commercialization of ZYN ULTRA in June 2026 under recent FDA guidance. The company leads the industry in securing FDA authorizations for smoke-free products.

Business Impact

As of December 31, 2025, PMI estimated over 43 million legal-age consumers worldwide used its smoke-free products. The smoke-free business accounted for approximately 42% of PMI’s second-quarter 2026 total net revenues.

PMI has invested over $16 billion since 2008 to develop and commercialize innovative smoke-free products. The company operates manufacturing facilities in Aurora, Colorado; Owensboro, Kentucky; and Wilson, North Carolina.

What the Numbers Show

The authorization of high-nicotine variants (9mg and 11mg) indicates a strategic shift toward capturing consumers seeking stronger nicotine delivery without tobacco leaf. With smoke-free products already contributing 42% of Q2FY26 net revenues, expanding the authorized portfolio supports revenue diversification away from traditional cigarettes.